{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T11:04:16Z","timestamp":1793703856407,"version":"4.5.1"},"reference-count":261,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100009253","name":"European Association for the Study of the Liver","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009253","id-type":"DOI","asserted-by":"crossref"}]},{"name":"DFG"},{"name":"Helmut and Hannelore Greve Foundation"},{"name":"YAEL-Foundation"},{"DOI":"10.13039\/501100000272","name":"NIHR","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Birmingham Liver Biomedical Research Centre"},{"name":"EU Marie Curie scheme"},{"DOI":"10.13039\/501100012295","name":"Newcastle Biomedical Research Centre","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012295","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journal-of-hepatology.eu","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.jhep.2017.03.022","type":"journal-article","created":{"date-parts":[[2017,4,18]],"date-time":"2017-04-18T01:00:12Z","timestamp":1492477212000},"page":"145-172","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1369,"title":["EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis"],"prefix":"10.1016","volume":"67","author":[{"given":"Gideon M.","family":"Hirschfield","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Beuers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Corpechot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Invernizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Marzioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Schramm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2017.03.022_b0005","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/j.jhep.2015.06.031","article-title":"Changing nomenclature for PBC: from \u2018cirrhosis\u2019 to \u2018cholangitis\u2019","volume":"63","author":"Beuers","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.03.022_b0010","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1016\/S0140-6736(10)61965-4","article-title":"Primary biliary cirrhosis","volume":"377","author":"Selmi","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2017.03.022_b0015","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1146\/annurev-pathol-020712-164014","article-title":"The immunobiology and pathophysiology of primary biliary cirrhosis","volume":"8","author":"Hirschfield","year":"2013","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.jhep.2017.03.022_b0020","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.jhep.2015.02.023","article-title":"New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond","volume":"62","author":"Beuers","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.03.022_b0025","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/nrgastro.2016.201","article-title":"Primary biliary cholangitis in 2016: High-definition PBC: biology, models and therapeutic advances","volume":"14","author":"Webb","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2017.03.022_b0030","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1053\/j.gastro.2012.12.005","article-title":"Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic Acid","volume":"144","author":"Carbone","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2017.03.022_b0035","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1053\/j.gastro.2014.08.029","article-title":"Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study","volume":"147","author":"Lammers","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2017.03.022_b0040","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1136\/gutjnl-2014-308351","article-title":"Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study","volume":"65","author":"Trivedi","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2017.03.022_b0045","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.gastro.2003.08.022","article-title":"Pediatric-onset primary biliary cirrhosis","volume":"125","author":"Dahlan","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2017.03.022_b0050","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/1471-230X-12-92","article-title":"Autoimmune hepatitis type 2 associated with an unexpected and transient presence of primary biliary cirrhosis-specific antimitochondrial antibodies: a case study and review of the literature","volume":"12","author":"Invernizzi","year":"2012","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.jhep.2017.03.022_b0055","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1055\/s-0034-1383726","article-title":"Environmental factors in primary biliary cirrhosis","volume":"34","author":"Juran","year":"2014","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhep.2017.03.022_b0060","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jaut.2015.08.016","article-title":"Using GWAS to identify genetic predisposition in hepatic autoimmunity","volume":"66","author":"Webb","year":"2016","journal-title":"J Autoimmun"},{"key":"10.1016\/j.jhep.2017.03.022_b0065","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1055\/s-0034-1383725","article-title":"Genetics and epigenetics of primary biliary cirrhosis","volume":"34","author":"Bianchi","year":"2014","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhep.2017.03.022_b0070","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1159\/000440705","article-title":"Worldwide incidence of autoimmune liver disease","volume":"33","author":"Jepsen","year":"2015","journal-title":"Dig Dis"},{"key":"10.1016\/j.jhep.2017.03.022_b0075","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1111\/liv.12434","article-title":"Rising incidence and prevalence of primary biliary cirrhosis: a large population-based study","volume":"34","author":"Boonstra","year":"2014","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2017.03.022_b0080","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1055\/s-0034-1383730","article-title":"The new epidemiology of primary biliary cirrhosis","volume":"34","author":"Griffiths","year":"2014","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhep.2017.03.022_b0085","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/hep.28859","article-title":"Large-scale characterization study of patients with antimitochondrial antibodies but nonestablished primary biliary cholangitis","volume":"65","author":"Dahlqvist","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.03.022_b0090","doi-asserted-by":"crossref","DOI":"10.1038\/srep25906","article-title":"Evolving trends in female to male incidence and male mortality of primary biliary cholangitis","volume":"6","author":"Lleo","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhep.2017.03.022_b0095","doi-asserted-by":"crossref","first-page":"J187","DOI":"10.1016\/j.jaut.2011.11.012","article-title":"The X chromosome and immune associated genes","volume":"38","author":"Bianchi","year":"2012","journal-title":"J Autoimmun"},{"key":"10.1016\/j.jhep.2017.03.022_b0100","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1002\/hep.28128","article-title":"Risk stratification in autoimmune cholestatic liver diseases: Opportunities for clinicians and trialists","volume":"63","author":"Trivedi","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.03.022_b0105","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1002\/hep.28991","article-title":"New therapeutic concepts in bile acid transport and signalling for management of cholestasis","volume":"65","author":"Trauner","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.03.022_b0110","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1002\/hep.28965","article-title":"The ascending pathophysiology of cholestatic liver disease","volume":"65","author":"Jansen","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.03.022_b0115","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1056\/NEJMoa0810440","article-title":"Primary biliary cirrhosis associated with HLA, IL12A and IL12RB2 variants","volume":"360","author":"Hirschfield","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2017.03.022_b0120","doi-asserted-by":"crossref","first-page":"8019","DOI":"10.1038\/ncomms9019","article-title":"International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways","volume":"6","author":"Cordell","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhep.2017.03.022_b0125","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/hep.28550","article-title":"Soluble adenylyl cyclase regulates bile salt-induced apoptosis in human cholangiocytes","volume":"64","author":"Chang","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.03.022_b0130","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.jaut.2016.08.006","article-title":"Hydrophobic bile acids suppress expression of AE2 in biliary epithelial cells and induce bile duct inflammation in primary biliary cholangitis","volume":"75","author":"Hisamoto","year":"2016","journal-title":"J Autoimmun"},{"key":"10.1016\/j.jhep.2017.03.022_b0135","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1002\/hep.23810","article-title":"The biliary HCO(3)(-) umbrella: a unifying hypothesis on pathogenetic and therapeutic aspects of fibrosing cholangiopathies","volume":"52","author":"Beuers","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.03.022_b0140","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1002\/hep.27715","article-title":"Liver alkaline phosphatase: a missing link between choleresis and biliary inflammation","volume":"61","author":"Poupon","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.03.022_b0145","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/hep.26365","article-title":"The impact of primary biliary cirrhosis on perceived quality of life: the UK-PBC National Study","volume":"58","author":"Mells","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.03.022_b0150","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1111\/apt.13794","article-title":"The inter-relationship of symptom severity and quality of life in 2055 patients with primary biliary cholangitis","volume":"44","author":"Dyson","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2017.03.022_b0155","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1053\/gast.2002.36027","article-title":"Survival and symptom progression in a geographically based cohort of paients with primary biliary cirrhosis: follow-up for up to 28 years","volume":"123","author":"Prince","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2017.03.022_b0160","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S0168-8278(05)80139-4","article-title":"Primary biliary cirrhosis: survival of a large cohort of symptomatic and asymptomatic patients followed for 24 years","volume":"20","author":"Mahl","year":"1994","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.03.022_b0165","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/0016-5085(80)90571-5","article-title":"Clinical pattern and course of disease in primary biliary cirrhosis based on an analysis of 236 patients","volume":"78","author":"Christensen","year":"1980","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2017.03.022_b0170","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/hep.510230108","article-title":"Time course of histological progression in primary biliary cirrhosis","volume":"23","author":"Locke","year":"1996","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.03.022_b0175","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1053\/jhep.2000.20240","article-title":"The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis","volume":"32","author":"Corpechot","year":"2000","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.03.022_b0180","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1001\/jama.281.20.1900","article-title":"Are guidelines following guidelines? The methodological quality of clinical practice guidelines in the peer-reviewed medical literature","volume":"281","author":"Shaneyfelt","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.jhep.2017.03.022_b0185","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jhep.2009.04.009","article-title":"EASL Clinical Practice Guidelines: management of cholestatic liver diseases","volume":"51","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.03.022_b0190","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1038\/ajg.2014.131","article-title":"ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury","volume":"109","author":"Chalasani","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2017.03.022_b0195","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/hep.21583","article-title":"A sensitive bead assay for antimitochondrial antibodies: Chipping away at AMA-negative primary biliary cirrhosis","volume":"45","author":"Oertelt","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.03.022_b0200","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.jaut.2010.09.005","article-title":"PBC screen: an IgG\/IgA dual isotype ELISA detecting multiple mitochondrial and nuclear autoantibodies specific for primary biliary cirrhosis","volume":"35","author":"Liu","year":"2010","journal-title":"J Autoimmun"},{"key":"10.1016\/j.jhep.2017.03.022_b0205","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1002\/hep.21828","article-title":"Antimitochondrial antibodies in acute liver failure: implications for primary biliary cirrhosis","volume":"46","author":"Leung","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.03.022_b0210","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1002\/hep.510270303","article-title":"Characterization of antimitochondrial antibodies in health adults","volume":"27","author":"Mattalia","year":"1998","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.03.022_b0215","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S0895-4356(00)00370-X","article-title":"Primary biliary cirrhosis among atomic bomb survivors in Nagasaki, Japan","volume":"54","author":"Ohba","year":"2001","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jhep.2017.03.022_b0220","article-title":"Mercury, autoimmunity, and environmental factors on cheyenne river sioux tribal lands","volume":"2014","author":"Ong","year":"2014","journal-title":"Autoimmune Dis"},{"key":"10.1016\/j.jhep.2017.03.022_b0225","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/hep.24630","article-title":"Immunoglobulin M levels inversely correlate with CD40 ligand promoter methylation in patients with primary biliary cirrhosis","volume":"55","author":"Lleo","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.03.022_b0230","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/0016-5085(86)90972-8","article-title":"Azathioprine and prognosis in primary biliary cirrhosis","volume":"90","author":"Christensen","year":"1986","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2017.03.022_b0235","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/S0168-8278(99)80098-1","article-title":"Clinical and biochemical expression of the histopathological lesions of primary biliary cirrhosis, UDCA-PBC Group","volume":"30","author":"Poupon","year":"1999","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.03.022_b0240","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1478-3231.2004.0918.x","article-title":"Biochemical markers of liver fibrosis and lymphocytic piecemeal necrosis in UDCA-treated patients with primary biliary cirrhosis","volume":"24","author":"Corpechot","year":"2004","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2017.03.022_b0245","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1136\/gut.51.2.265","article-title":"Hyperlipidaemic state and cardiovascular risk in primary biliary cirrhosis","volume":"51","author":"Longo","year":"2002","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2017.03.022_b0250","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1136\/gut.2005.079814","article-title":"Hypercholesterolaemia is not associated with early atherosclerotic lesions in primary biliary cirrhosis","volume":"55","author":"Allocca","year":"2006","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2017.03.022_b0255","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.jhep.2004.08.002","article-title":"Liver autoimmune serology: a consensus statement from the committee for autoimmune serology of the International Autoimmune Hepatitis Group","volume":"41","author":"Vergani","year":"2004","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.03.022_b0260","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1055\/s-2007-979469","article-title":"Interpreting serological tests in diagnosing autoimmune liver diseases","volume":"27","author":"Invernizzi","year":"2007","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhep.2017.03.022_b0265","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/S0140-6736(96)04410-8","article-title":"Natural history of early primary biliary cirrhosis","volume":"348","author":"Metcalf","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2017.03.022_b0270","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.cld.2008.02.003","article-title":"Antimitochondrial antibody-negative primary biliary cirrhosis","volume":"12","author":"Hirschfield","year":"2008","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.jhep.2017.03.022_b0275","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/BF00432479","article-title":"Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis)","volume":"379","author":"Ludwig","year":"1978","journal-title":"Virchows Arch"},{"key":"10.1016\/j.jhep.2017.03.022_b0280","first-page":"1257","article-title":"Primary biliary cirrhosis","volume":"60","author":"Scheuer","year":"1967","journal-title":"Proc R Soc Med"},{"key":"10.1016\/j.jhep.2017.03.022_b0285","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0025-6196(11)63652-5","article-title":"Ludwig Symposium on biliary disorders\u2013part II. Pathologic features and evolution of primary biliary cirrhosis and primary sclerosing cholangitis","volume":"73","author":"Scheuer","year":"1998","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jhep.2017.03.022_b0290","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1440-1827.2009.02500.x","article-title":"Application of a new histological staging and grading system for primary biliary cirrhosis to liver biopsy specimens: Interobserver agreement","volume":"60","author":"Nakanuma","year":"2010","journal-title":"Pathol Int"},{"key":"10.1016\/j.jhep.2017.03.022_b0295","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/MCG.0b013e31827234e4","article-title":"Application and validation of a new histologic staging and grading system for primary biliary cirrhosis","volume":"47","author":"Harada","year":"2013","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.jhep.2017.03.022_b0300","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.humpath.2012.09.017","article-title":"Evaluation of a new histologic staging and grading system for primary biliary cirrhosis in comparison with classical systems","volume":"44","author":"Kakuda","year":"2013","journal-title":"Hum Pathol"},{"key":"10.1016\/j.jhep.2017.03.022_b0305","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1111\/j.1572-0241.2006.00699.x","article-title":"Prognosis of ursodeoxycholic Acid-treated patients with primary biliary cirrhosis. Results of a 10-yr cohort study involving 297 patients","volume":"101","author":"ter Borg","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2017.03.022_b0310","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1053\/j.gastro.2005.12.029","article-title":"Excellent long-term survival in patients with primary biliary cirrhosisand biochemical response to ursodeoxycholic acid","volume":"130","author":"Pares","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2017.03.022_b0315","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1002\/hep.22428","article-title":"Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis","volume":"48","author":"Corpechot","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.03.022_b0320","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1007\/s00535-009-0090-2","article-title":"Mortality rate of patients with asymptomatic primary biliary cirrhosis diagnosed at age 55 years or older is similar to that of the general population","volume":"44","author":"Kubota","year":"2009","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.jhep.2017.03.022_b0325","doi-asserted-by":"crossref","first-page":"S798","DOI":"10.1016\/S0168-8278(15)31380-5","article-title":"Age, bilirubin and albumin, regardless of sex, are the strongest independent predictors of biochemical response and transplantation-free survival in patients with primary biliary cirrhosis","volume":"62","author":"Cheung","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.03.022_b0330","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/liv.12560","article-title":"Fatigue and pruritus at onset identify a more aggressive subset of primary biliary cirrhosis","volume":"35","author":"Quarneti","year":"2015","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2017.03.022_b0335","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.jhep.2010.05.026","article-title":"The independent effects of fatigue and UDCA therapy on mortality in primary biliary cirrhosis: Results of a 9 year follow-up","volume":"53","author":"Jones","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.03.022_b0340","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1136\/gut.49.2.276","article-title":"Jaundice in non-cirrhotic primary bilairy cirrhosis: the premature ductopenic variant","volume":"49","author":"Vleggaar","year":"2001","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2017.03.022_b0345","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1136\/gut.2005.080317","article-title":"Four year follow up of fatigue in a geographically defined primary biliary cirrhosis patient cohort","volume":"55","author":"Jones","year":"2006","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2017.03.022_b0350","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1136\/gut.2003.023937","article-title":"Asymptomatic primary biliary cirrhosis: clinical features, prognosis, and symptom progression in a large population based cohort","volume":"53","author":"Prince","year":"2004","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2017.03.022_b0355","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/j.1478-3231.2009.02122.x","article-title":"Variability of perceived fatigue in primary biliary cirrhosis: implications for symptom assessment","volume":"30","author":"Newton","year":"2010","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2017.03.022_b0360","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1136\/gut.20.2.137","article-title":"Serum bilirubin: a prognostic factor in primary biliary cirrhosis","volume":"20","author":"Shapiro","year":"1979","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2017.03.022_b0365","first-page":"1148","article-title":"Is the Mayo model for predicting survival useful after the introduction of ursodeoxycholic acid treatment for primary biliary cirrhosis?","volume":"23","author":"Kilmurry","year":"1996","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.03.022_b0370","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1002\/hep.22517","article-title":"Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay","volume":"48","author":"Mayo","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.03.022_b0375","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/j.1572-0241.2003.07257.x","article-title":"Characterization and clinical impact of antinuclear antibodies in primary biliary cirrhosis","volume":"98","author":"Muratori","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2017.03.022_b0380","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1136\/gut.2003.036558","article-title":"Prevalence and clinical significance of isotype specific antinuclear antibodies in primary biliary cirrhosis","volume":"54","author":"Rigopoulou","year":"2005","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2017.03.022_b0385","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1002\/hep.21172","article-title":"Correlation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis","volume":"43","author":"Wesierska-Gadek","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.03.022_b0390","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1111\/hepr.12423","article-title":"Autoantibody status and histological variables influence biochemical response to treatment and long-term outcomes in Japanese patients with primary biliary cirrhosis","volume":"45","author":"Nakamura","year":"2015","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jhep.2017.03.022_b0395","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1136\/gut.2005.075002","article-title":"Clinical features and prognosis of primary biliary cirrhosis associated with systemic sclerosis","volume":"55","author":"Rigamonti","year":"2006","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2017.03.022_b0400","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/hep.21472","article-title":"Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis","volume":"45","author":"Nakamura","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.03.022_b0405","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1002\/hep.1840080127","article-title":"Serum hyaluronate in primary biliary cirrhosis\u2013a biochemical marker for progressive liver damage","volume":"8","author":"Nyberg","year":"1988","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.03.022_b0410","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1002\/hep.1840190314","article-title":"Predictive factors in ursodeoxycholic acid-treated patients with primary biliary cirrhosis: role of serum markers of connective tissue","volume":"19","author":"Poupon","year":"1994","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.03.022_b0415","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jhep.2014.01.029","article-title":"Optimising risk stratification in primary biliary cirrhosis: AST\/platelet ratio index predicts outcome independent of ursodeoxycholic acid response","volume":"60","author":"Trivedi","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.03.022_b0420","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/ajg.2015.118","article-title":"Serum wisteria floribunda agglutinin-positive Mac-2-binding protein level predicts liver fibrosis and prognosis in primary biliary cirrhosis","volume":"110","author":"Umemura","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2017.03.022_b0425","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0131658","article-title":"Serum cell death biomarkers for prediction of liver fibrosis and poor prognosis in primary biliary cirrhosis","volume":"10","author":"Sekiguchi","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2017.03.022_b0430","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/hep.25599","article-title":"Noninvasive elastography-based assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis","volume":"56","author":"Corpechot","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.03.022_b0435","first-page":"887","article-title":"Performance and utility of transient elastography and noninvasive markers of liver fibrosis in primary biliary cirrhosis","volume":"43","author":"Floreani","year":"2011","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.jhep.2017.03.022_b0440","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.1365-2036.2007.03585.x","article-title":"Transient elastography to assess hepatic fibrosis in primary biliary cirrhosis","volume":"27","author":"Gomez-Dominguez","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2017.03.022_b0445","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jhep.2015.04.006","article-title":"EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis","volume":"63","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.03.022_b0450","first-page":"194A","article-title":"Relationships between biochemical response to UDCA and progression of liver stiffness as determined by Fibroscan in patients with PBC","volume":"64","author":"Corpechot","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.03.022_b0455","doi-asserted-by":"crossref","first-page":"S177","DOI":"10.1016\/S0168-8278(16)00105-7","article-title":"Fibroscan improves the ability of the new prognostic scoring systems to predict outcomes of PBC","volume":"64","author":"Corpechot","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.03.022_b0460","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1002\/hep.25993","article-title":"Determination of reliability criteria for liver stiffness evaluation by transient elastography","volume":"57","author":"Boursier","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.03.022_b0465","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM198301063080101","article-title":"The prognostic importance of clinical and histologic features in asymptomatic and symptomatic primary biliary cirrhosis","volume":"308","author":"Roll","year":"1983","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2017.03.022_b0470","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1002\/hep.510290603","article-title":"Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis","volume":"29","author":"Poupon","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.03.022_b0475","doi-asserted-by":"crossref","first-page":"S805","DOI":"10.1016\/S0168-8278(15)31394-5","article-title":"Histological stage is relevant for risk-stratification in primary biliary cirrhosis","volume":"62","author":"Carbone","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.03.022_b0480","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.gcb.2010.02.004","article-title":"Triple therapy with ursodeoxycholic acid, budesonide and mycophenolate mofetil in patients with features of severe primary biliary cirrhosis not responding to ursodeoxycholic acid alone","volume":"34","author":"Rabahi","year":"2010","journal-title":"Gastroenterol Clin Biol"},{"key":"10.1016\/j.jhep.2017.03.022_b0485","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1053\/gast.2002.31880","article-title":"Primary biliary cirrhosis: incidence and predictive factors of cirrhosis development in ursodiol-treated patients","volume":"122","author":"Corpechot","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2017.03.022_b0490","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1038\/ajg.2010.216","article-title":"Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis","volume":"105","author":"Kumagi","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2017.03.022_b0495","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1053\/j.gastro.2008.07.019","article-title":"Portal hypertension and primary biliary cirrhosis: effect of long-term ursodeoxycholic acid treatment","volume":"135","author":"Huet","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2017.03.022_b0500","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/hep.23637","article-title":"American Association for the Study of Liver Diseases endpoints conference: design and endpoints for clinical trials in primary biliary cirrhosis","volume":"52","author":"Silveira","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.03.022_b0505","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1478-3231.1999.tb00020.x","article-title":"Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid","volume":"19","author":"Angulo","year":"1999","journal-title":"Liver"},{"key":"10.1016\/j.jhep.2017.03.022_b0510","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1053\/j.gastro.2009.01.003","article-title":"Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid","volume":"136","author":"Kuiper","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2017.03.022_b0515","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1007\/s00535-009-0051-9","article-title":"Early biochemical response to ursodeoxycholic acid predicts symptom development in patients with asymptomatic primary biliary cirrhosis","volume":"44","author":"Azemoto","year":"2009","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.jhep.2017.03.022_b0520","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.jhep.2011.02.031","article-title":"Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome","volume":"55","author":"Corpechot","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.03.022_b0525","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/hep.26322","article-title":"Early biochemical response to ursodeoxycholic acid and long-term prognosis of primary biliary cirrhosis: results of a 14-year cohort study","volume":"58","author":"Zhang","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.03.022_b0530","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1053\/j.gastro.2015.07.061","article-title":"Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy","volume":"149","author":"Lammers","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2017.03.022_b0535","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1002\/hep.28017","article-title":"The UK-PBC risk scores: Derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cirrhosis","volume":"63","author":"Carbone","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.03.022_b0540","first-page":"507A","article-title":"Convergence of Two Predictive Models of Risk Reduction in Patients with Primary Biliary Cirrhosis","volume":"62","author":"Hansen","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.03.022_b0545","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1056\/NEJMct074694","article-title":"Ursodeoxycholic acid for the treatment of primary biliary cirrhosis","volume":"357","author":"Lindor","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2017.03.022_b0550","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/hep.22906","article-title":"Primary biliary cirrhosis","volume":"50","author":"Lindor","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.03.022_b0555","series-title":"Primary biliary cirrhosis: evidence-based gastroenterology and hepatology","year":"2010"},{"key":"10.1016\/j.jhep.2017.03.022_b0560","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1056\/NEJM199405123301903","article-title":"Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDCA-PBC Study Group","volume":"330","author":"Poupon","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2017.03.022_b0565","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/0016-5085(94)90021-3","article-title":"Ursodeoxycholic acid in the treatment of primary biliary cirrhosis","volume":"106","author":"Lindor","year":"1994","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2017.03.022_b0570","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1002\/hep.1840190512","article-title":"The Canadian Multicenter Double-blind Randomized Controlled Trial of ursodeoxycholic acid in primary biliary cirrhosis","volume":"19","author":"Heathcote","year":"1994","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.03.022_b0575","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/j.1440-1746.1994.tb01237.x","article-title":"A two year controlled trial examining the effectiveness of ursodeoxycholic acid in primary biliary cirrhosis","volume":"9","author":"Turner","year":"1994","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2017.03.022_b0580","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/S0016-5085(97)70183-5","article-title":"Combined analysis of randomized trials of ursodeoxycholic acid in primary biliary cirrhosis","volume":"113","author":"Poupon","year":"1997","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2017.03.022_b0585","first-page":"759","article-title":"A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis","volume":"22","author":"Combes","year":"1995","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.03.022_b0590","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1046\/j.1365-2036.1998.00395.x","article-title":"A randomized trial in primary biliary cirrhosis comparing ursodeoxycholic acid in daily doses of either 10 mg\/kg or 20 mg\/kg. Dutch Multicentre PBC Study Group","volume":"12","author":"Van Hoogstraten","year":"1998","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2017.03.022_b0595","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/S0140-6736(98)11293-X","article-title":"Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis","volume":"354","author":"Goulis","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2017.03.022_b0600","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1111\/j.1572-0241.2006.00634.x","article-title":"Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis: a meta-analysis of randomized controlled trials","volume":"101","author":"Shi","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2017.03.022_b0605","first-page":"CD000551","article-title":"Ursodeoxycholic acid for primary biliary cirrhosis","volume":"12","author":"Rudic","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jhep.2017.03.022_b0610","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/ncpgasthep0521","article-title":"Drug insight: Mechanisms and sites of action of ursodeoxycholic acid in cholestasis","volume":"3","author":"Beuers","year":"2006","journal-title":"Nat Clin Pract Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2017.03.022_b0615","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1002\/hep.25992","article-title":"alpha5 beta1-integrins are sensors for tauroursodeoxycholic acid in hepatocytes","volume":"57","author":"Gohlke","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.03.022_b0620","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jhep.2012.02.014","article-title":"Effect of ursodeoxycholic acid on bile acid profiles and intestinal detoxification machinery in primary biliary cirrhosis and health","volume":"57","author":"Dilger","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.03.022_b0625","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1053\/j.gastro.2005.06.019","article-title":"Efficacy and safety of ursodeoxycholic acid vs. cholestyramine in intrahepatic cholestasis of pregnancy","volume":"129","author":"Kondrackiene","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2017.03.022_b0630","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1053\/j.gastro.2012.08.004","article-title":"Efficacy of ursodeoxycholic acid in treating intrahepatic cholestasis of pregnancy: a meta-analysis","volume":"143","author":"Bacq","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2017.03.022_b0635","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1111\/j.1572-0241.2007.01235.x","article-title":"Ursodeoxycholic acid for patients with primary biliary cirrhosis: an updated systematic review and meta-analysis of randomized clinical trials using Bayesian approach as sensitivity analyses","volume":"102","author":"Gong","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2017.03.022_b0640","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/nrgastro.2013.151","article-title":"Bile acid receptors as targets for drug development","volume":"11","author":"Schaap","year":"2014","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2017.03.022_b0645","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms10713","article-title":"Mutations in the nuclear bile acid receptor FXR cause progressive familial intrahepatic cholestasis","volume":"7","author":"Gomez-Ospina","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhep.2017.03.022_b0650","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1053\/j.gastro.2014.12.005","article-title":"Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid","volume":"148","author":"Hirschfield","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2017.03.022_b0655","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"A placebo-controlled trial of obeticholic acid in primary biliary cholangitis","volume":"375","author":"Nevens","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2017.03.022_b0660","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1053\/jhep.2003.50266","article-title":"Pharmacokinetics and pharmacodynamic action of budesonide in early- and late-stage primary biliary cirrhosis","volume":"38","author":"Hempfling","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.03.022_b0665","first-page":"695","article-title":"Combination of ursodeoxycholic acid and glucocorticoids upregulates the AE2 alternate promoter in human liver cells","volume":"118","author":"Arenas","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jhep.2017.03.022_b0670","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/S0016-5085(99)70351-3","article-title":"Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial","volume":"117","author":"Leuschner","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2017.03.022_b0675","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1002\/hep.20646","article-title":"Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three-year randomized trial","volume":"41","author":"Rautiainen","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.03.022_b0680","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/hep.510310209","article-title":"Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid","volume":"31","author":"Angulo","year":"2000","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.03.022_b0685","doi-asserted-by":"crossref","first-page":"24533","DOI":"10.18632\/oncotarget.4528","article-title":"Optimal drug regimens for primary biliary cirrhosis: a systematic review and network meta-analysis","volume":"6","author":"Zhu","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.jhep.2017.03.022_b0690","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000000609","article-title":"Network meta-analysis of randomized controlled trials: efficacy and safety of UDCA-based therapies in primary biliary cirrhosis","volume":"94","author":"Zhu","year":"2015","journal-title":"Medicine"},{"key":"10.1016\/j.jhep.2017.03.022_b0695","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1002\/hep.27744","article-title":"Fibrates and cholestasis","volume":"62","author":"Ghonem","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.03.022_b0700","first-page":"5407","article-title":"Systematic review and meta-analysis: bezafibrate in patients with primary biliary cirrhosis","volume":"9","author":"Yin","year":"2015","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.jhep.2017.03.022_b0705","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s00535-014-0998-z","article-title":"Biochemical responses to bezafibrate improve long-term outcome in asymptomatic patients with primary biliary cirrhosis refractory to UDCA","volume":"50","author":"Tanaka","year":"2015","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.jhep.2017.03.022_b0710","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s00535-002-1102-7","article-title":"Bezafibrate treatment: a new medical approach for PBC patients?","volume":"38","author":"Kanda","year":"2003","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.jhep.2017.03.022_b0715","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/ajg.2015.20","article-title":"A prospective randomized controlled study of long-term combination therapy using ursodeoxycholic acid and bezafibrate in patients with primary biliary cirrhosis and dyslipidemia","volume":"110","author":"Hosonuma","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2017.03.022_b0720","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/liv.12290","article-title":"Bezafibrate normalizes alkaline phosphatase in primary biliary cirrhosis patients with incomplete response to ursodeoxycholic acid","volume":"34","author":"Lens","year":"2014","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2017.03.022_b0725","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1111\/j.1572-0241.2002.05944.x","article-title":"Fenofibrate treatment in patients with primary biliary cirrhosis","volume":"97","author":"Ohira","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2017.03.022_b0730","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1365-2036.2010.04512.x","article-title":"Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid","volume":"33","author":"Levy","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2017.03.022_b0735","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.clinre.2015.02.011","article-title":"Fenofibrate is effective adjunctive therapy in the treatment of primary biliary cirrhosis: A meta-analysis","volume":"39","author":"Grigorian","year":"2015","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.jhep.2017.03.022_b0740","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/apt.13465","article-title":"Combined ursodeoxycholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes","volume":"43","author":"Cheung","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2017.03.022_b0745","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1111\/j.1572-0241.2002.05645.x","article-title":"Is bezafibrate histologically effective for primary biliary cirrhosis?","volume":"97","author":"Yano","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2017.03.022_b0750","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/j.1572-0241.2002.05413.x","article-title":"Investigation into the efficacy of bezafibrate against primary biliary cirrhosis, with histological references from cases receiving long term monotherapy","volume":"97","author":"Kurihara","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2017.03.022_b0755","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1007\/s10620-016-4250-y","article-title":"Long-term fenofibrate treatment in primary biliary cholangitis improves biochemistry but Not the UK-PBC risk score","volume":"61","author":"Hegade","year":"2016","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jhep.2017.03.022_b0760","first-page":"2757","article-title":"Combination therapy of fenofibrate and ursodeoxycholic acid in patients with primary biliary cirrhosis who respond incompletely to UDCA monotherapy: a meta-analysis","volume":"9","author":"Zhang","year":"2015","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.jhep.2017.03.022_b0765","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.cgh.2013.11.030","article-title":"Good maternal and fetal outcomes for pregnant women with primary biliary cirrhosis","volume":"12","author":"Trivedi","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2017.03.022_b0770","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ejogrb.2015.03.020","article-title":"Rifampicin in the treatment of severe intrahepatic cholestasis of pregnancy","volume":"189","author":"Geenes","year":"2015","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.jhep.2017.03.022_b0775","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1155\/2008\/969826","article-title":"Role of plasmapheresis in the treatment of severe pruritus in pregnant patients with primary biliary cirrhosis: case reports","author":"Alallam","year":"2008","journal-title":"Can J Gastroenterol"},{"key":"10.1016\/j.jhep.2017.03.022_b0780","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jhep.2010.09.002","article-title":"Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue","volume":"54","author":"Boberg","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.03.022_b0785","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1111\/j.1365-2036.2012.05223.x","article-title":"Review article: overlap syndromes and autoimmune liver disease","volume":"36","author":"Trivedi","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2017.03.022_b0790","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1016\/j.cgh.2013.08.039","article-title":"Cholestatic phenotypes of autoimmune hepatitis","volume":"12","author":"Czaja","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2017.03.022_b0795","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.ejim.2008.12.011","article-title":"Transitions between variant forms of primary biliary cirrhosis during long-term follow-up","volume":"20","author":"Lindgren","year":"2009","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.jhep.2017.03.022_b0800","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/hep.21229","article-title":"Development of autoimmune hepatitis in patients with typical primary biliary cirrhosis","volume":"44","author":"Poupon","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.03.022_b0805","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1097\/MEG.0000000000000075","article-title":"Sequential presentation of primary biliary cirrhosis and autoimmune hepatitis","volume":"26","author":"Efe","year":"2014","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2017.03.022_b0810","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/hep.510280203","article-title":"Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy","volume":"28","author":"Chazouilleres","year":"1998","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.03.022_b0815","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.jhep.2015.06.030","article-title":"EASL Clinical Practice Guidelines: autoimmune hepatitis","volume":"63","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.03.022_b0820","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1002\/hep.23584","article-title":"Diagnosis and management of autoimmune hepatitis","volume":"51","author":"Manns","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.03.022_b0825","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0168-8278(99)80297-9","article-title":"International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis","volume":"31","author":"Alvarez","year":"1999","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.03.022_b0830","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/hep.22322","article-title":"Simplified criteria for the diagnosis of autoimmune hepatitis","volume":"48","author":"Hennes","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.03.022_b0835","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1111\/j.1478-3231.2009.01986.x","article-title":"Significance of antibodies to soluble liver antigen\/liver pancreas: a large French study","volume":"29","author":"Eyraud","year":"2009","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2017.03.022_b0840","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1055\/s-2001-12906","article-title":"Presence of SLA\/LP autoantibodies in patients with primary biliary cirrhosis as a marker for secondary autoimmune hepatitis (overlap syndrome)","volume":"126","author":"Kanzler","year":"2001","journal-title":"Dtsch Med Wochenschr"},{"key":"10.1016\/j.jhep.2017.03.022_b0845","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1038\/ajg.2009.126","article-title":"The serological profile of the autoimmune hepatitis\/primary biliary cirrhosis overlap syndrome","volume":"104","author":"Muratori","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2017.03.022_b0850","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1053\/jhep.2001.27562","article-title":"Autoimmune hepatitis with incidental histologic features of bile duct injury","volume":"34","author":"Czaja","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.03.022_b0855","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/hep.22380","article-title":"Long-term follow-up of antimitochondrial antibody-positive autoimmune hepatitis","volume":"48","author":"O'Brien","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.03.022_b0860","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.cgh.2012.02.010","article-title":"Patients with autoimmune hepatitis who have antimitochondrial antibodies need long-term follow-up to detect late development of primary biliary cirrhosis","volume":"10","author":"Dinani","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2017.03.022_b0865","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/ajg.2009.616","article-title":"Autoimmune hepatitis-PBC overlap syndrome: a simplified scoring system may assist in the diagnosis","volume":"105","author":"Neuhauser","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2017.03.022_b0870","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1007\/s12016-015-8516-5","article-title":"The natural history and prognosis of primary biliary cirrhosis with clinical features of autoimmune hepatitis","volume":"50","author":"Yang","year":"2016","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.jhep.2017.03.022_b0875","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.cgh.2013.09.021","article-title":"Factors associated with response to therapy and outcome of patients with primary biliary cirrhosis with features of autoimmune hepatitis","volume":"12","author":"Ozaslan","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2017.03.022_b0880","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.jhep.2005.10.017","article-title":"Long term outcome and response to therapy of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome","volume":"44","author":"Chazouilleres","year":"2006","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.03.022_b0885","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1002\/hep.510280210","article-title":"Frequency and nature of the variant syndromes of autoimmune liver disease","volume":"28","author":"Czaja","year":"1998","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.03.022_b0890","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1365-2036.2008.03722.x","article-title":"Autoimmune hepatitis overlap syndromes: an evaluation of treatment response, long-term outcome and survival","volume":"28","author":"Al-Chalabi","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2017.03.022_b0895","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jaut.2012.10.004","article-title":"Epigenetic considerations and the clinical reevaluation of the overlap syndrome between primary biliary cirrhosis and autoimmune hepatitis","volume":"41","author":"Wang","year":"2013","journal-title":"J Autoimmun"},{"key":"10.1016\/j.jhep.2017.03.022_b0900","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1002\/hep.510290409","article-title":"Characterization of the overlap syndrome of primary biliary cirrhosis (PBC) and autoimmune hepatitis: evidence for it being a hepatitic form of PBC in genetically susceptible individuals","volume":"29","author":"Lohse","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.03.022_b0905","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1136\/gut.2005.065862","article-title":"Development, validation and evaluation of the PBC-40, a disease specific health related quality of life measure for primary biliary cirrhosis","volume":"54","author":"Jacoby","year":"2005","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2017.03.022_b0910","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.jhep.2005.12.012","article-title":"Characterisation of the associations and impact of symptoms in primary biliary cirrhosis using a disease specific quality of life measure","volume":"44","author":"Newton","year":"2006","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.03.022_b0915","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/hep.26909","article-title":"Pruritus in cholestasis: facts and fiction","volume":"60","author":"Beuers","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.03.022_b0920","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1056\/NEJM197309272891306","article-title":"The presentation and diagnosis of 100 patients with primary biliary cirrhosis","volume":"289","author":"Sherlock","year":"1973","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2017.03.022_b0925","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/S0016-5085(76)80016-9","article-title":"The biliary system in primary biliary cirrhosis. A study by endoscopic retrograde cholangiopancreatography","volume":"70","author":"Summerfield","year":"1976","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2017.03.022_b0930","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0016-5085(66)80071-9","article-title":"Cholestyramine for long term relief of the priritus complicating intrahepatic cholestasis","volume":"50","author":"Datta","year":"1966","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2017.03.022_b0935","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1046\/j.1365-2362.2000.00606.x","article-title":"Effect of cholestyramine on bile acid patterns and synthesis during administration of ursodeoxycholic acid in man","volume":"30","author":"Rust","year":"2000","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.jhep.2017.03.022_b0940","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1002\/hep.23821","article-title":"The potent bile acid sequestrant colesevelam is not effective in cholestatic pruritus: results of a double-blind, randomized, placebo-controlled trial","volume":"52","author":"Kuiper","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.03.022_b0945","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1002\/hep.25748","article-title":"Serum autotaxin is increased in pruritus of cholestasis, but not of other origin and responds to therapeutic interventions","volume":"56","author":"Kremer","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.03.022_b0950","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/0016-5085(88)90442-8","article-title":"Treatment of pruritus in primary biliary cirrhosis with rifampicin. Results of a double-blind, crossover, randomized trial","volume":"94","author":"Ghent","year":"1988","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2017.03.022_b0955","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/S0140-6736(89)91608-5","article-title":"Comparison of rifampicin with phenobarbitone for treatment of pruritus in biliary cirrhosis","volume":"1","author":"Bachs","year":"1989","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2017.03.022_b0960","first-page":"488","article-title":"Treatment of pruritus in primary biliary cirrhosis with rifampicin. Results of a double-blind, cross-over, randomized trial","volume":"94","author":"Podesta","year":"1991","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2017.03.022_b0965","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1016\/0016-5085(92)90335-V","article-title":"Effects of long-term rifampicin administration in primary biliary cirrhosis","volume":"102","author":"Bachs","year":"1992","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2017.03.022_b0970","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1111\/j.1572-0241.2007.01200.x","article-title":"The efficacy and safety of bile acid binding agents, opioid antagonists or rifampin in the treatment of cholestasis-associated pruritus","volume":"102","author":"Tandon","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2017.03.022_b0975","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1111\/j.1478-3231.2006.01326.x","article-title":"Rifampin is safe for treatment of pruritus due to chronic cholestasis: a meta-analysis of prospective randomized-controlled trials","volume":"26","author":"Khurana","year":"2006","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2017.03.022_b0980","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1136\/gut.50.3.436","article-title":"Hepatitis and liver dysfunction with rifampicin therapy for pruritus in primary biliary cirrhosis","volume":"50","author":"Prince","year":"2002","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2017.03.022_b0985","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1111\/j.1365-2125.2011.04158.x","article-title":"Severe coagulopathy caused by rifampicin in patients with primary sclerosing cholangitis and refractory pruritus","volume":"73","author":"Sampaziotis","year":"2012","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jhep.2017.03.022_b0990","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/0016-5085(92)90102-5","article-title":"A controlled trial of naloxone infusions for the pruritus of chronic cholestasis","volume":"102","author":"Bergasa","year":"1992","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2017.03.022_b0995","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1053\/gast.1997.v113.pm9322521","article-title":"Oral naltrexone for cholestatic pruritus-a double-blind, placebo-controlled study","volume":"113","author":"Wolfhagen","year":"1997","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2017.03.022_b1000","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0168-8278(02)00318-5","article-title":"Efficacy and safety of oral naltrexone treatment for pruritus of cholestasis, a crossover, double blind, placebo-controlled study","volume":"37","author":"Terg","year":"2002","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.03.022_b1005","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1093\/qjmed\/95.8.547","article-title":"Opiate antagonist therapy for the pruritus of cholestasis: the avoidance of opioid withdrawal-like reactions","volume":"95","author":"Jones","year":"2002","journal-title":"Q J Med"},{"key":"10.1016\/j.jhep.2017.03.022_b1010","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/S0016-5085(03)00879-5","article-title":"Pain as a complication of use of opiate antagonists for symptom control in cholestasis","volume":"125","author":"McRae","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2017.03.022_b1015","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0016-5085(00)70225-3","article-title":"Florid opioid withdrawal-like reaction precipitated by naltrexone in a patient with chronic cholestasis","volume":"118","author":"Jones","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2017.03.022_b1020","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1002\/hep.21553","article-title":"Sertraline as a first-line treatment for cholestatic pruritus","volume":"45","author":"Mayo","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.03.022_b1025","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/hep.21370","article-title":"Gabapentin in patients with the pruritus of cholestasis: a double-blind, randomized, placebo-controlled trial","volume":"44","author":"Bergasa","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.03.022_b1030","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1002\/hep.21271","article-title":"Biliary drainage transiently relieves intractable pruritus in primary biliary cirrhosis","volume":"44","author":"Beuers","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.03.022_b1035","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1002\/hep.21185","article-title":"Nasobiliary drainage for cholestatic pruritus","volume":"43","author":"Hofmann","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.03.022_b1040","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/apt.13449","article-title":"The safety and efficacy of nasobiliary drainage in the treatment of refractory cholestatic pruritus: a multicentre European study","volume":"43","author":"Hegade","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2017.03.022_b1045","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.jhep.2010.02.031","article-title":"Treatment of resistant pruritus from cholestasis with albumin dialysis: combined analysis of patients from three centers","volume":"53","author":"Pares","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.03.022_b1050","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.jhep.2012.04.023","article-title":"Cholestasis-induced pruritus treated with ultraviolet B phototherapy: an observational case series study","volume":"57","author":"Decock","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.03.022_b1055","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1111\/j.1365-2036.2012.04994.x","article-title":"\u201cOut-patient\u201d albumin dialysis for cholestatic patients with intractable itch","volume":"35","author":"Leckie","year":"2012","journal-title":"Aliment Pharmacol Therap"},{"key":"10.1016\/j.jhep.2017.03.022_b1060","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/hep.510290229","article-title":"Quality of life before and after liver transplantation for cholestatic liver disease","volume":"29","author":"Gross","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.03.022_b1065","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1053\/j.gastro.2010.05.009","article-title":"Lysophosphatidic acid is a potential mediator of cholestatic pruritus","volume":"139","author":"Kremer","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2017.03.022_b1070","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/S0140-6736(17)30319-7","article-title":"Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study","volume":"389","author":"Hegade","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2017.03.022_b1075","first-page":"167A","article-title":"Fatigue, mental health and depression in patients with primary biliary cirrhosis (PBC)","volume":"24","author":"Huet","year":"1996","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.03.022_b1080","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1136\/gut.43.5.705","article-title":"Fatigue in primary biliary cirrhosis","volume":"43","author":"Cauch-Dudek","year":"1998","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2017.03.022_b1085","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/j.1572-0241.2000.01857.x","article-title":"Impact of fatigue on the quality of life in patients with primary biliary cirrhosis","volume":"95","author":"Huet","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2017.03.022_b1090","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1053\/gast.2002.32993","article-title":"The true impact of fatigue in primary biliary cirrhosis: a population study","volume":"122","author":"Goldblatt","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2017.03.022_b1095","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/hep.22371","article-title":"Cognitive impairment in primary biliary cirrhosis: symtpom impact and potential aetiology","volume":"48","author":"Newton","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.03.022_b1100","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.cgh.2008.04.013","article-title":"A pilot study of peripheral muscle function in primary biliary cirrhosis: potential implications for fatigue pathogenesis","volume":"6","author":"Hollingsworth","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2017.03.022_b1105","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.jhep.2013.04.017","article-title":"The effect of liver transplantation on fatigue in patients with primary biliary cirrhosis: a prospective study","volume":"59","author":"Carbone","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.03.022_b1110","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1093\/qjmed\/hcn043","article-title":"An integrated care pathway improves quality of life in Primary Biliary Cirrhosis","volume":"101","author":"Jones","year":"2008","journal-title":"QJM"},{"key":"10.1016\/j.jhep.2017.03.022_b1115","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/qjmed\/hch078","article-title":"Patterns of autoimmunity in PBC patients and their families","volume":"97","author":"Watt","year":"2004","journal-title":"QJM"},{"key":"10.1016\/j.jhep.2017.03.022_b1120","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jhep.2010.02.022","article-title":"Loss of capacity to recover from acidosis in repeat exercise is strongly associated with fatigue in primary biliary cirrhosis","volume":"53","author":"Hollingsworth","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.03.022_b1125","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/PL00009532","article-title":"Primary biliary cirrhosis, sicca complex, and dysphagia","volume":"12","author":"Mang","year":"1997","journal-title":"Dysphagia"},{"key":"10.1016\/j.jhep.2017.03.022_b1130","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1136\/ard.2002.003889","article-title":"Oral pilocarpine for the treatment of ocular symptoms in patients with Sjogren's syndrome: a randomised 12 week controlled study","volume":"62","author":"Tsifetaki","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jhep.2017.03.022_b1135","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ajo.2004.02.010","article-title":"Therapeutic effect of cevimeline on dry eye in patients with Sjogren's syndrome: a randomized, double-blind clinical study","volume":"138","author":"Ono","year":"2004","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jhep.2017.03.022_b1140","first-page":"465","article-title":"Diagnosis and management of Sjogren syndrome","volume":"79","author":"Kruszka","year":"2009","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.jhep.2017.03.022_b1145","unstructured":"Excellence NIfHaC. Raynaud's Phenomenon NICE Clinical Knowledge Summary. 2014 [cited; Available from: http:\/\/cks.nice.org.uk\/raynauds-phenomenon \u2013 !scenario."},{"key":"10.1016\/j.jhep.2017.03.022_b1150","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jhep.2004.11.035","article-title":"Severity of cholestasis and advanced histological stage but not menopausal status are the major risk factors for osteoporosis in primary biliary cirrhosis","volume":"42","author":"Guanabens","year":"2005","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.03.022_b1155","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.cld.2008.02.005","article-title":"Osteoporosis in primary biliary cirrhosis: pathogenesis and treatment","volume":"12","author":"Pares","year":"2008","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.jhep.2017.03.022_b1160","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1053\/j.gastro.2010.02.016","article-title":"Low bone mass and severity of cholestasis affect fracture risk in patients with primary biliary cirrhosis","volume":"138","author":"Guanabens","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2017.03.022_b1165","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1002\/hep.26466","article-title":"Randomized trial comparing monthly ibandronate and weekly alendronate for osteoporosis in patients with primary biliary cirrhosis","volume":"58","author":"Guanabens","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.03.022_b1170","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.4065\/77.10.1031","article-title":"Oral bisphosphonates and upper gastrointestinal tract problems: what is the evidence?","volume":"77","author":"Cryer","year":"2002","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jhep.2017.03.022_b1175","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/MJT.0b013e3181d7e1d3","article-title":"Parenteral bisphosphonates for osteoporosis in patients with primary biliary cirrhosis","volume":"18","author":"Treeprasertsuk","year":"2011","journal-title":"Am J Ther"},{"key":"10.1016\/j.jhep.2017.03.022_b1180","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/j.1365-2036.2004.01890.x","article-title":"Transdermal hormone replacement therapy improves vertebral bone density in primary biliary cirrhosis: results of a 1-year controlled trial","volume":"19","author":"Pereira","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2017.03.022_b1185","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1136\/gut.49.2.282","article-title":"Osteoporosis in primary biliary cirrhosis revisited","volume":"49","author":"Newton","year":"2001","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2017.03.022_b1190","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/S0016-5085(88)80029-5","article-title":"Fat-soluble vitamin nutriture in primary biliary cirrhosis","volume":"95","author":"Kaplan","year":"1988","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2017.03.022_b1195","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1111\/j.1572-0241.2001.04134.x","article-title":"Fat-soluble vitamin levels in patients with primary biliary cirrhosis","volume":"96","author":"Phillips","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2017.03.022_b1200","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.dld.2010.03.015","article-title":"Bile salts and cholestasis","volume":"42","author":"Maillette de Buy Wenniger","year":"2010","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.jhep.2017.03.022_b1205","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/0016-5085(85)90642-0","article-title":"Lipoprotein abnormalities in primary biliary cirrhosis. Association with hepatic lipase inhibition as well as altered cholesterol esterification","volume":"89","author":"Jahn","year":"1985","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2017.03.022_b1210","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1136\/gut.12.10.830","article-title":"Portal hypertension in primary biliary cirrhosis","volume":"12","author":"Kew","year":"1971","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2017.03.022_b1215","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/0016-5085(89)90526-X","article-title":"Prospective evaluation of esophageal varices in primary biliary cirrhosis: development, natural history, and influence on survival","volume":"96","author":"Gores","year":"1989","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2017.03.022_b1220","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1097\/01.pas.0000213286.65907.ea","article-title":"Liver transplantation in precirrhotic biliary tract disease: Portal hypertension is frequently associated with nodular regenerative hyperplasia and obliterative portal venopathy","volume":"30","author":"Abraham","year":"2006","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.jhep.2017.03.022_b1225","doi-asserted-by":"crossref","first-page":"e66","DOI":"10.1097\/MCG.0b013e3181f18c4e","article-title":"Varices in early histological stage primary biliary cirrhosis","volume":"45","author":"Ali","year":"2011","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.jhep.2017.03.022_b1230","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.cgh.2007.02.031","article-title":"Prevalence and predictors of esophageal varices in patients with primary biliary cirrhosis","volume":"5","author":"Levy","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2017.03.022_b1235","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1136\/gut.2004.040832","article-title":"Which patients with primary biliary cirrhosis or primary sclerosing cholangitis should undergo endoscopic screening for oesophageal varices detection?","volume":"54","author":"Bressler","year":"2005","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2017.03.022_b1240","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.jhep.2015.05.022","article-title":"Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension","volume":"63","author":"de Franchis","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.03.022_b1245","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1002\/hep.510260508","article-title":"Hepatocellular carcinoma in primary biliary cirrhosis and its impact on outcomes","volume":"26","author":"Jones","year":"1997","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.03.022_b1250","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.jhep.2011.12.001","article-title":"EASL-EORTC clinical practice guidelines: Management of hepatocellular carcinoma","volume":"56","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.03.022_b1255","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.jhep.2012.04.015","article-title":"Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR)","volume":"57","author":"Adam","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.03.022_b1260","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1097\/TP.0b013e31827afb3a","article-title":"Evolving frequency and outcomes of liver transplantation based on etiology of liver disease","volume":"95","author":"Singal","year":"2013","journal-title":"Transplantation"},{"key":"10.1016\/j.jhep.2017.03.022_b1265","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.jhep.2013.09.020","article-title":"Autoimmune liver disease, autoimmunity and liver transplantation","volume":"60","author":"Carbone","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.03.022_b1270","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1002\/hep.26972","article-title":"Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation","volume":"59","author":"Martin","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.03.022_b1275","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.jhep.2015.10.006","article-title":"Electronic address eee. EASL Clinical Practice Guidelines: Liver transplantation","volume":"64","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.03.022_b1280","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jhep.2013.02.019","article-title":"The impact of liver transplantation on the phenotype of primary biliary cirrhosis patients in the UK-PBC cohort","volume":"59","author":"Pells","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.03.022_b1285","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/lt.23566","article-title":"Long-term management of the successful adult liver transplant: 2012 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation","volume":"19","author":"Lucey","year":"2013","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2017.03.022_b1290","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1111\/j.1600-6143.2010.03038.x","article-title":"Recurrent primary biliary cirrhosis after liver transplantation","volume":"10","author":"Silveira","year":"2010","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jhep.2017.03.022_b1295","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.jhep.2015.07.038","article-title":"Preventive administration of UDCA after liver transplantation for primary biliary cirrhosis is associated with a lower risk of disease recurrence","volume":"63","author":"Bosch","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.03.022_b1300","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3109\/17453054.2011.548794","article-title":"Development of an evidence-based patient information medium: empowering newly diagnosed patients with primary biliary cirrhosis","volume":"34","author":"Pearce","year":"2011","journal-title":"J Vis Commun Med"},{"key":"10.1016\/j.jhep.2017.03.022_b1305","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1111\/j.1478-3231.2007.01500.x","article-title":"The role of psychological factors in the fatigue of primary biliary cirrhosis","volume":"27","author":"Blackburn","year":"2007","journal-title":"Liver Int"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827817301861?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827817301861?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,17]],"date-time":"2020-05-17T16:21:58Z","timestamp":1589732518000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827817301861"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":261,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["S0168827817301861"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2017.03.022","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2017.03.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}